Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience.

ABSTRACT:

Introduction

Enfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a human monoclonal antibody targeting nectin-4. No validated biomarker predictive of or correlated with response exists for EV. Cutaneous toxicity is among the most common EV-related toxicities and typically emerges in early cycles. This retrospective experience of patients with urothelial cancer treated with EV monotherapy evaluated whether EV-related cutaneous toxicity correlated with improved outcomes including progression-free (PFS) and overall (OS) survival and overall response rate (ORR).

Patients and methods

Patients treated with EV monotherapy at Johns Hopkins were identified, and baseline characteristic

SUBMITTER: Vlachou E 

PROVIDER: S-EPMC11199536 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature